Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsOpinionInsulin complements Eris Lifesciences' diabetes portfolio, market share gains key

    Insulin complements Eris Lifesciences' diabetes portfolio, market share gains key

    Eris' joint venture to market insulin adds a potential revenue stream, but product efficacy will play an important role in the success of the new venture

    R. Sree Ram
    December 07, 2021 / 09:00 IST
    Representative image
    • PRO Panorama

      Moneycontrol Pro Panorama | A new AI order is reshaping real estate 

      Nov 21, 2025 / 03:34 PM IST

      Moneycontrol's Pro Panorama November 21 edition: CAG audit reveals problems in Delhi's broken bus services, India’s private bank...

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts